Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz I, Perelló A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Máhr K, Schenker M, Sohn J, Lee KS, Shepherd CJ, Oelmann E, Sarker SJ, Prendergast A, Marosics P, Moosa A, Lawrence C, Coetzee C, Mousa K, Cortés J. Schmid P, et al. Among authors: kristeleit h. JAMA Oncol. 2019 Nov 1;5(11):1556-1564. doi: 10.1001/jamaoncol.2019.2526. JAMA Oncol. 2019. PMID: 31465093 Free PMC article.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Battisti NML, Kingston B, King J, Denton A, Waters S, Sita-Lumsden A, Rehman F, Stavraka C, Kristeleit H, Sawyer E, Houghton D, Davidson N, Howell S, Choy J, Harper P, Roylance R, Fharat R, Mohammed K, Ring A, Johnston S. Battisti NML, et al. Among authors: kristeleit h. Breast Cancer Res Treat. 2019 Apr;174(3):731-740. doi: 10.1007/s10549-019-05134-x. Epub 2019 Jan 17. Breast Cancer Res Treat. 2019. PMID: 30656459
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J. Molife LR, et al. Among authors: kristeleit h. Cancer Chemother Pharmacol. 2013 Dec;72(6):1213-22. doi: 10.1007/s00280-013-2286-7. Epub 2013 Oct 2. Cancer Chemother Pharmacol. 2013. PMID: 24085260 Clinical Trial.
IGN-311. Igeneon.
Kristeleit H. Kristeleit H. Curr Opin Investig Drugs. 2005 Dec;6(12):1272-9. Curr Opin Investig Drugs. 2005. PMID: 16370394
Systemic treatment of non-small-cell lung cancer.
Lal R, Enting D, Kristeleit H. Lal R, et al. Among authors: kristeleit h. Eur J Cancer. 2011 Sep;47 Suppl 3:S375-7. doi: 10.1016/S0959-8049(11)70209-X. Eur J Cancer. 2011. PMID: 21944021 Review. No abstract available.
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer Centre.
Russell B, Moss C, Tsotra E, Gousis C, Josephs D, Enting D, Karampera C, Khan M, Roca J, Sita-Lumsden A, Owczarczyk K, Wylie H, Haire A, Smith D, Zaki K, Swampillai A, Lei M, Manik V, Michalarea V, Kristeleit R, Mera A, Sawyer E, Flanders L, De Francesco I, Papa S, Ross P, Spicer J, Dann B, Jogia V, Shaunak N, Kristeleit H, Rigg A, Montes A, Van Hemelrijck M, Dolly S. Russell B, et al. Among authors: kristeleit h. Cancers (Basel). 2022 Jan 6;14(2):266. doi: 10.3390/cancers14020266. Cancers (Basel). 2022. PMID: 35053432 Free PMC article.
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
McKenzie DR, Muñoz-Ruiz M, Monin L, Alaguthurai T, Lechmere T, Abdul-Jawad S, Graham C, Pollock E, Graham R, Sychowska K, Seow J, Tremain C, Gousis C, Domingo-Vila C, Cooper J, Vidler J, Owczarczyk K, Swampillai A, Kristeleit H, Malim MH, Fields P, Patten PEM, Papa S, North BV, Tree T, Doores KJ, Hayday AC, Irshad S. McKenzie DR, et al. Among authors: kristeleit h. Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12. Cancer Cell. 2021. PMID: 34678151 Free PMC article. No abstract available.
19 results